---
title: "InMed Pharmaceuticals Inc. (INM.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/INM.US.md"
symbol: "INM.US"
name: "InMed Pharmaceuticals Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-19T16:10:30.288Z"
locales:
  - [en](https://longbridge.com/en/quote/INM.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/INM.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/INM.US.md)
---

# InMed Pharmaceuticals Inc. (INM.US)

## Company Overview

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.inmedpharma.com](https://www.inmedpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: C (0.42)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 107 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 285.22% |  |
| Net Profit YoY | -2.39% |  |
| P/B Ratio | 0.33 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2255882.68 |  |
| Revenue | 4942633.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -112.65% | E |
| Profit Margin | -172.17% | E |
| Gross Margin | 0.00% | E |
| Revenue YoY | 285.22% | A |
| Net Profit YoY | -2.39% | C |
| Total Assets YoY | -1.57% | D |
| Net Assets YoY | -1.85% | D |
| Cash Flow Margin | 87.63% | C |
| OCF YoY | 285.22% | A |
| Turnover | 0.54 | C |
| Gearing Ratio | 24.55% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - InMed Pharmaceuticals Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "285.22%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-2.39%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.33",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2255882.68",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4942633.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-112.65%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-172.17%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "285.22%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-2.39%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.57%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-1.85%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "87.63%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "285.22%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.54",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "24.55%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.27 | 79/190 | - | - | - |
| PB | 0.33 | 13/190 | 0.46 | 0.35 | 0.26 |
| PS (TTM) | 0.46 | 17/190 | 0.94 | 0.66 | 0.55 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2024-02-29T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.45 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/INM.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/INM.US/norm.md)
- [Related News](https://longbridge.com/en/quote/INM.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/INM.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**